Lillyemerging competitorMedium

Pipeline activity

Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026

Pressure score

Momentum score

Why This Matters

Lilly is an emerging emerging competitor with Phase III activity on Pipeline activity in Endocrinology · Obesity; while behind Roche (Phase II), accelerated readouts could compress Roche's strategic window.

Competitive Assessment

Threat type: emerging competitor
Development stage: Phase III
Stage gap: Competitor is one development stage ahead, creating near-term competitive pressure.
Market share risk: Late-stage competitor could compress launch window and payer leverage before approval.

Strategic Action

Align with signal posture: monitor. Monitor emerging competitor activity and refresh competitive intelligence after material readouts.

Overlap Analysis

Mechanism overlap

No explicit mechanism overlap identified in available text.

Indication overlap

Limited indication overlap evidenced in corpus text.

Source Analysis

Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026

The Phase 3 LIBRETTO-432 study of Retevmo as adjuvant therapy in RET fusion-positive NSCLC will be highlighted at ASCO 2026.

Source: Lilly

View source document

Related Signal

Roche to Present Phase II Data on Enicepatide and Petrelintide at ADA 2026

Open signal

Competitor Position

Not enough competitive findings for a race view.